Regardless of advances in most cancers immunotherapy, some sufferers don’t reply to those remedies or change into unresponsive over time. Eikon Therapeutics’ lead drug candidate might tackle these limitations. This program is presently in medical testing for 2 widespread sorts of most cancers and Eikon has raised $381 million in IPOs to assist this drug and others in its pipeline. […]